Advanstar launches portal for medical titles

Share this article:

Advanstar Communications unveiled a centralized physician portal for its healthcare group, integrating sites for its five primary care and seven specialty titles into one address,

The site will offer advertisers “a highly targeted and highly trackable vehicle for marketers to reach authenticated doctors,” said Advanstar Life Sciences Group EVP Steve Morris. Advanstar expects to have 100,000 registered users, all authenticated against the American Medical Association database, in 2008.

In addition, Advanstar's pharmacy title Drug Topics will increase its digital platform emphasis in February with an accelerated schedule of five editions per month – one in print and four delivered digitally – to keep readers up to date on pharma industry news.

“The pharmaceutical market is increasingly employing e-promotion, with doctors seeking easy access to a diverse range of information resources and pharmaceutical marketers looking for increased return on their advertising investment,” said Morris.

The portal will offer article summaries from over 300-peer reviewed journals, coding and reimbursement tools, formulary status tools, a comprehensive library of CME programs, customizable patient education, coverage of more than 80 major medical conferences and valuable practice management advice, the publisher said.

Advanstar titles include Medical Economics, Drug Topics, Formulary, Patient Care, Geriatrics, Contemporary Ob/Gyn, Dermatology Times and RN Magazine.

The move comes as medical publishers scramble to retool their online platforms amid plummeting ad spending from the pharmaceutical sector, particularly on primary care titles.

In September, Elsevier launched a portal for its more than 100 oncology titles,, seeking to beef up its online advertising revenue in one of the few categories where pharma spending is expanding. In October, incoming Medical Economics publisher Trevor Deal said the title would be looking more at non-pharma advertising opportunities as well as projects, live meetings, symposia and online to make up for the slump in pharma ads. And last month, Ascend Media announced it would close three medical titles, sell its dental titles and consider selling the remainder of its healthcare division.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...